NCT06174766View on ClinicalTrials.gov

A Study to Evaluate Efficacy and Safety of HGP2102 in Essential Hypertension Patients

PHASE3RecruitingINTERVENTIONAL
Enrollment

324

Participants

Timeline

Start Date

May 10, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Hypertension
Interventions
DRUG

HGP2102-1

Test drug

DRUG

HGP2102-2

Test drug

DRUG

RLD2209-1

Control drug

DRUG

RLD2209-2

Control drug

Trial Locations (1)

03722

RECRUITING

Sevrance hosptal, Seodaemun-gu

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT06174766 - A Study to Evaluate Efficacy and Safety of HGP2102 in Essential Hypertension Patients | Biotech Hunter | Biotech Hunter